(Q30455596)

21 June 2017

title

Angiogenic inhibition in high-grade gliomas: past, present and future (English)

1 reference

21 June 2017

Jasmin Jo

1

1 reference

21 June 2017

David Schiff

series ordinal

2

1 reference

21 June 2017

Benjamin Purow

series ordinal

3

1 reference

21 June 2017

publication date

1 June 2012

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

21 June 2017

published in

1 reference

21 June 2017

volume

12

1 reference

21 June 2017

issue

6

1 reference

21 June 2017

page(s)

733-747

1 reference

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 June 2017

cites work

1 reference

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.

21 January 2018

1 reference

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...]

21 January 2018

1 reference

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

Angiogenesis in life, disease and medicine

21 January 2018

1 reference

21 January 2018

1 reference

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

What Is the Evidence That Tumors Are Angiogenesis Dependent?

21 January 2018

1 reference

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

21 January 2018

1 reference

Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis.

21 January 2018

1 reference

Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis.

21 January 2018

1 reference

Mechanisms of angiogenesis in gliomas

21 January 2018

1 reference

Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model

21 January 2018

1 reference

The biology of VEGF and its receptors

21 January 2018

1 reference

The role of neuropilins in cancer

21 January 2018

1 reference

Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis.

21 January 2018

1 reference

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

21 January 2018

1 reference

Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma

21 January 2018

1 reference

Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment

21 January 2018

1 reference

Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs

21 January 2018

1 reference

Vascular endothelial growth factor production is stimulated by gangliosides and TGF-beta isoforms in human glioma cells in vitro

21 January 2018

1 reference

Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape

21 January 2018

1 reference

Transforming growth factors beta(1) (TGF-beta(1)) and TGF-beta(2) promote glioma cell migration via Up-regulation of alpha(V)beta(3) integrin expression.

21 January 2018

1 reference

Interleukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1.

21 January 2018

1 reference

Dual pathways of tubular morphogenesis of vascular endothelial cells by human glioma cells: vascular endothelial growth factor/basic fibroblast growth factor and interleukin-8.

21 January 2018

1 reference

Interleukin-6 overexpression as a marker of malignancy in human gliomas.

21 January 2018

1 reference

Distribution of endogenous tumour necrosis factor alpha in gliomas

21 January 2018

1 reference

Effects of retinoic acid and tumor necrosis factor alpha on GL-15 glioblastoma cells

21 January 2018

1 reference

Integrins: molecular determinants of glioma invasion

21 January 2018

1 reference

Proteases and the biology of glioma invasion

21 January 2018

1 reference

Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma

21 January 2018

1 reference

Cancerous stem cells can arise from pediatric brain tumors

21 January 2018

1 reference

Identification of human brain tumour initiating cells

21 January 2018

1 reference

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

21 January 2018

1 reference

A perivascular niche for brain tumor stem cells

21 January 2018

1 reference

Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1.

21 January 2018

1 reference

Potential therapeutic implications of cancer stem cells in glioblastoma

21 January 2018

1 reference

Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions

21 January 2018

1 reference

Molecular analysis of ex-vivo CD133+ GBM cells revealed a common invasive and angiogenic profile but different proliferative signatures among high grade gliomas.

21 January 2018

1 reference

Antiangiogenic therapy in malignant glioma: promise and challenge

21 January 2018

1 reference

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

21 January 2018

1 reference

Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy

21 January 2018

1 reference

Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor

21 January 2018

1 reference

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.

21 January 2018

1 reference

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma

21 January 2018

1 reference

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study

21 January 2018

1 reference

Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab

21 January 2018

1 reference

Bevacizumab and irinotecan for recurrent oligodendroglial tumors.

21 January 2018

1 reference

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

21 January 2018

1 reference

Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas

21 January 2018

1 reference

A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma

21 January 2018

1 reference

Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme

21 January 2018

1 reference

Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety

21 January 2018

1 reference

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.

21 January 2018

1 reference

Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases

21 January 2018

1 reference

Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors

21 January 2018

1 reference

Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience

21 January 2018

1 reference

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

21 January 2018

1 reference

Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas

21 January 2018

1 reference

VEGF-Trap: a VEGF blocker with potent antitumor effects

21 January 2018

1 reference

VEGF Trap induces antiglioma effect at different stages of disease

21 January 2018

1 reference

Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study

21 January 2018

1 reference

VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma.

21 January 2018

1 reference

The emerging role of anti-angiogenic therapy for malignant glioma

21 January 2018

1 reference

Molecular targeted therapies and chemotherapy in malignant gliomas.

21 January 2018

1 reference

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

21 January 2018

1 reference

Phase II study of sunitinib malate in patients with recurrent high-grade glioma.

21 January 2018

1 reference

Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).

21 January 2018

1 reference

Mechanisms of adverse effects of anti-VEGF therapy for cancer

21 January 2018

1 reference

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis

21 January 2018

1 reference

VEGF inhibition and renal thrombotic microangiopathy

21 January 2018

1 reference

Reversible posterior leukoencephalopathy syndrome in a child treated with bevacizumab.

21 January 2018

1 reference

Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

21 January 2018

1 reference

Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells

21 January 2018

1 reference

CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo.

21 January 2018

1 reference

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion

21 January 2018

1 reference

Antiangiogenic therapies for high-grade glioma

21 January 2018

1 reference

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

21 January 2018

1 reference

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

The hypoxic response of tumors is dependent on their microenvironment.

21 January 2018

1 reference

Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma

21 January 2018

1 reference

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

21 January 2018

1 reference

High-grade glioma before and after treatment with radiation and Avastin: initial observations

21 January 2018

1 reference

Bevacizumab does not increase the risk of remote relapse in malignant glioma.

21 January 2018

1 reference

Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab.

21 January 2018

1 reference

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

21 January 2018

1 reference

Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker

21 January 2018

1 reference

A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients

21 January 2018

1 reference

Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker

21 January 2018

1 reference

Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma

21 January 2018

1 reference

Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study

21 January 2018

1 reference

Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab

21 January 2018

1 reference

Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan

21 January 2018

1 reference

Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept

21 January 2018

1 reference

Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis.

21 January 2018

1 reference

Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis.

21 January 2018

1 reference

Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model

21 January 2018

1 reference

High-dose antiangiogenic therapy for glioblastoma: less may be more?

21 January 2018

1 reference

Contribution of bone marrow–derived endothelial cells to human tumor vasculature

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERN.12.53

1 reference

21 June 2017

1 reference